Vaborbactam

Synonym(s): RPX7009

Class: Beta-lactamase inhibitor (heterocyclic boron)

Details of activity:	Binds reversibly to beta-lactamases with a focus on class A enzymes, especially KPC enzymes. Fixed combination with meropenem
Combined with other compounds:	Yes
Description:	Synthetic compound. 2017 approved in fixed combination with meropenem (Vabomere, Vaborem)
Institute where first reported:	Rempex Pharmaceuticals, Melinta TherapeuticsMenarini
Year first mentioned:	2013
Highest developmental phase:	Approved by FDA in 2017
Development status:	Approved

Chemical structure(s):
Canonical SMILES:	C1=CSC(=C1)CC(=O)N[C@H]2CC[C@@H](CC(=O)O)OB2O
Isomeric SMILES:	B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O
InChI:	InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1
InChI Key:	IOOWNWLVCOUUEX-WPRPVWTQSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/56649692

External links:
Main Source:	https://pubmed.ncbi.nlm.nih.gov/25782055/
Citations:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655098/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985712/ https://www.tandfonline.com/doi/full/10.1080/14787210.2020.1756775